Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.59 |
| ▸ | CTSK | P43235 | 14/20 | 0.51 |
| ▸ | CTSL | P07711 | 6/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024444 | 1.00 | CTSS (0.59) | CTSSCTSKCTSLFPR2TP53 | |
| SCHEMBL14020921 | 0.85 | CTSS (0.70) | CTSSCTSKCTSL | |
| SCHEMBL4800562 | 0.85 | CTSS (0.70) | CTSSCTSKCTSL | |
| Hydrochloric Acid SCHEMBL14110438 | 0.84 | CTSK (0.60) | CTSSCTSKCTSL | |
| Hydrochloric Acid SCHEMBL14110440 | 0.84 | CTSK (0.60) | CTSSCTSKCTSL | |
| SCHEMBL4971768 | 0.82 | CTSK (0.46) | CTSSCTSKCTSLFPR2TP53 | |
| SCHEMBL14156388 | 0.82 | CTSS (0.54) | CTSSCTSKCTSL | |
| SCHEMBL4796774 | 0.80 | CTSS (0.56) | CTSSCTSKCTSL | |
| SCHEMBL4797556 | 0.80 | CTSS (0.56) | CTSSCTSKCTSL | |
| SCHEMBL3024781 | 0.77 | CTSS (0.67) | CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | disclosed |
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-7507755-B2 | Inhibitors of cathepsin s | IRM LLC (BM) | 2009-03-24 | — | — | US | disclosed |
| US-7501408-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | disclosed |
| US-7307095-B2 | Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide | IRM LLC (BM) | 2007-12-11 | — | — | US | disclosed |
| US-7256207-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2007-08-14 | — | — | US | disclosed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | disclosed |
| US-20050107368-A1 | Selective in presence of at least one other cathepsin isozyme; such as 1-(5,6-dichloro-benzimidazol-1-ylmethyl)-3,3-dimethyl-butyl [2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-hydroxymethyl-ethyl]carbamate | IRM LLC (BM) | 2005-05-19 | — | — | US | disclosed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885CTSL 11/4885 |
| US-20050107368-A1 | Selective in presence of at least one other cathepsin isozyme; such as 1-(5,6-dichloro-benzimidazol-1-ylmethyl)-3,3-dimethyl-butyl [2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-hydroxymethyl-ethyl]carbamate | CTSS, CTSZ, CTSV | CTSS 1/4885CTSK 7/4885CTSL 14/4885 |
| US-20050049244-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885CTSL 11/4885 |
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885CTSL 11/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885CTSL 11/4885 |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSE, CTSV | CTSS 1/4885CTSK 10/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.